Evolus Reports Q2 2025 Earnings Results with Revenue Growth and Guidance Update
Evolus (EOLS) reported Q2 2025 earnings with global net revenue of $69.4 million, a 4% increase, driven by Toxin and HA Gels revenue. The company raised its 2025 revenue guidance to $295 million to $305 million, reflecting strong performance from the Evolysse product launch.
Topics: Earnings Report Market Share Product Launch Revenue Growth Revenue Guidance